Loading
Forian Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wygod Max C, was filed 18 Feb 2025.
Forian Inc.: what insiders have been doing
Forian Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 23 October 2026, brought 17 filings signed by 10 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Compared with its exchange (3,167 companies, median 24 filings), a count of 17 filings is below the norm. The full history, which starts in 2021, counts 73 purchases against no sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 30.3 m USD and net income at -2.9 m USD.
No insider has bought Forian Inc. shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
155
Thresholds
n/a
Buy Volume
€2M
73 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleMax C. Wygod5 buys
Since the insiders bought
- -17.4%Entry US$3.56 · Close at T+365 US$2.94
- -34.1%Entry US$5.13 · Close at T+365 US$3.38
- -68.3%Entry US$11.98 · Close at T+365 US$3.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,496 of 26,248 companies
37.8
score / 100
Value42
Quality34
FCF yld4.3%
Earn yld-4.2%
EV/EBITDA·
ROE-18%
Gross mgn53%
Net mgn-9.5%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.17
Analyst consensus
Income statement
RevenueUS$30.3M
Gross profitUS$16.1M53% margin
EBITDA-US$2.3M-8% margin
Net income-US$2.9M-17.0% margin
Valuation
P/Book2.3x
Balance sheet & cash
Market capUS$67.8M
Total debtUS$12.1k
Free Cash FlowUS$2.9M
Debt / Equity0%
Profitability & ownership
ROE-18.0%
ROA-8.4%
% insiders51.8%
% institutions14.9%
Last declaration on 15 May 2026
Declarations155 total
250,000 sharesCommon StockSEC:0001140361-26-021733:1
99,784 sharesCommon StockSEC:0001140361-26-021730:1
1,831,526 sharesCommon StockSEC:0001140361-26-021733:2
2,455,533 sharesCommon StockSEC:0001140361-26-021733:0
37,583 sharesCommon StockSEC:0001140361-26-021728:0
5,000 sharesCommon StockSEC:0001140361-26-021725:0
150,000 sharesCommon StockSEC:0001140361-26-021724:0
28,757 sharesCommon StockSEC:0001140361-26-021726:0
171,184 sharesCommon StockSEC:0001140361-26-021732:0
1,278,927 sharesCommon StockSEC:0001140361-26-021731:0
139,610 sharesCommon StockSEC:0001140361-26-021727:0
5,000 sharesCommon StockSEC:0001140361-26-021730:0
5,000 sharesCommon StockSEC:0001140361-26-021729:0
4,918 shares@ US$2.101.8% of flowCommon StockSEC:0001140361-26-006090:0
18,077 shares@ US$2.126.8% of flowCommon StockSEC:0001140361-26-001191:0
17,777 shares@ US$2.156.9% of flowCommon StockSEC:0001140361-25-041738:0
150,000 shares@ US$2.24100.0% of flowCommon StockSEC:0001140361-25-040341:0
3,300 shares@ US$2.111.2% of flowCommon StockSEC:0001140361-25-034025:0
200,000 shares@ US$1.9389.0% of flowCommon StockSEC:0001140361-25-026270:0
200,000 shares@ US$1.9369.0% of flowCommon StockSEC:0001140361-25-026274:0
200,000 shares@ US$1.9392.0% of flowCommon StockSEC:0001140361-25-026272:0
7,769 shares@ US$2.067.1% of flowCommon StockSEC:0001140361-25-007616:0
5,426 shares@ US$2.766.8% of flowCommon StockSEC:0001140361-25-005046:0
4,971 shares@ US$2.762.7% of flowCommon StockSEC:0001140361-25-005045:0
880 shares@ US$2.960.7% of flowCommon StockSEC:0001140361-25-005048:0
Canonical exit: 15 May 2025 (T+90)
25 of 155 declarations
About Forian Inc.
Forian Inc. (ticker: FORA) is a United States-based company listed on NASDAQ, operating at the intersection of healthcare data, software, and analytics. The company develops proprietary solutions for life sciences companies, payers, and providers, with the stated goal of improving clients’ operational, clinical, and financial performance. Its profile is that of a healthcare data intelligence business rather than a broad-based enterprise software vendor.
Forian traces its corporate history to a 2020 formation tied to a business combination, with roots linked to Medical Outcomes Research Analytics (MOR). In its corporate materials, the company describes a mission focused on leveraging data to improve health outcomes and business value. It emphasizes an integrated healthcare data and analytics platform built around large-scale longitudinal US patient-level health records, proprietary taxonomies, behavioral segmentation, and advanced analytics layers. This data foundation supports research-ready data products and higher-value insight services.
Read moreShow less
Its main business lines center on data products, predictive analytics, and decision-support software. Forian serves organizations across life sciences and healthcare that need to better target markets, measure campaign effectiveness, understand patient journeys, support commercialization, and improve research and operational decision-making. The company’s competitive positioning is based on the depth of its proprietary datasets, its SOC-2 / HIPAA-compliant operating standards highlighted in public materials, and an integrated model that combines technology, data science, and domain expertise.
Geographically, Forian is primarily a US business. Its data assets and customer base are centered in the United States, which is also where the company is headquartered. For French-speaking investors, FORA therefore sits within the US small-cap healthcare and analytics universe on NASDAQ, with a business model driven more by data quality and platform differentiation than by traditional healthcare manufacturing or distribution.
Recent developments are important. SEC filings indicate a meaningful corporate transition: in 2025, shareholders approved a redomiciliation from Delaware to Maryland, and in May 2026 a merger/tender-offer process involving 2025 Acquisition Company, LLC and Bravo Merger Sub, Inc. was completed, according to a recent Form 4 filing. That suggests an ongoing restructuring of the company’s capital and legal framework, which is highly relevant for investors monitoring governance, ownership changes, and potential transaction-related outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
